Biohaven Pharmaceutical Ownership | Who Owns Biohaven Pharmaceutical?

Biohaven Pharmaceutical Ownership Summary

Biohaven Pharmaceutical is owned by 90.49% institutional investors, 11.16% insiders. Vanguard group is the largest institutional shareholder, holding 8.92% of BHVN shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.48% of its assets in Biohaven Pharmaceutical shares.

BHVN Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Biohaven Pharmaceutical	90.49%	11.16%	-1.65%
Sector	Healthcare Stocks	88.01%	8.90%	3.09%
Industry	Biotech Stocks	109.70%	8.77%	-18.47%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Vanguard group	8.41M	8.92%	$314.27M
Blackrock funding, inc. /de	7.67M	8.12%	$286.37M
Blackrock	6.17M	7.56%	$214.15M
Janus henderson group	5.90M	7.23%	$204.72M
Stifel financial	6.56M	6.95%	$244.99M
Suvretta capital management	5.20M	6.37%	$180.46M
State street	3.65M	4.47%	$126.69M
Price t rowe associates inc /md/	3.28M	4.03%	$114.01M
Rp management	2.94M	3.11%	$146.74M
Farallon capital management	2.25M	2.75%	$78.03M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Rp management	2.94M	64.43%	$146.74M
Oracle investment management	700.45K	22.68%	$24.31M
Suvretta capital management	5.20M	6.63%	$180.46M
5am venture management	469.97K	3.65%	$16.31M
Ars investment partners	1.04M	3.50%	$38.87M
Bison wealth	328.15K	2.92%	$17.95M
Altium capital management lp	250.00K	2.65%	$9.34M
Redmile group	1.09M	2.28%	$37.75M
First turn management	366.02K	2.07%	$12.70M
Dafna capital management	218.73K	1.81%	$7.59M

Top Buyers

Holder	Shares	% Assets	Change
Farallon capital management	2.25M	0.37%	1.45M
Suvretta capital management	5.20M	6.63%	1.20M
Jpmorgan chase	1.98M	0.01%	1.17M
Norges bank	902.57K	0.00%	902.57K
Bellevue group	2.04M	1.15%	890.85K

Top Sellers

Holder	Shares	% Assets	Change
Darwin global management	-	-	-1.48M
T. rowe price investment management	-	-	-1.23M
Point72 asset management	177.36K	0.02%	-732.24K
Ghost tree capital	-	-	-490.00K
Ubs asset management americas	76.67K	0.00%	-363.84K

New Positions

Holder	Shares	% Assets	Change	Value
Norges bank	902.57K	0.00%	902.57K	$33.71M
Emerald advisers	360.54K	0.52%	360.54K	$13.47M
Artal group	306.70K	0.27%	306.70K	$10.65M
Peregrine capital management	148.88K	0.16%	148.88K	$5.56M
Wcm investment management	106.67K	0.01%	106.67K	$3.82M

Sold Out

Holder	Change
Financial gravity asset management	-1.00
Allspring global investments	-2.00
Principal securities	-3.00
Tfc financial management	-3.00
Gps wealth strategies group	-5.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	263	11.91%	85,395,678	3.25%	90	1.02%	133	-5.00%	76	43.40%
Jun 30, 2024	233	-11.74%	82,690,329	11.42%	101	1.23%	139	6.11%	51	-30.14%
Mar 31, 2024	264	14.29%	74,214,259	2.75%	90	0.88%	131	-2.24%	73	46.00%
Dec 31, 2023	231	17.26%	72,225,057	16.64%	101	1.23%	134	63.41%	50	-28.57%
Sep 30, 2023	197	-3.90%	61,920,080	1.21%	90	1.13%	82	-3.53%	70	7.69%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	2.51M	2.48%	3.01K
iShares Russell 2000 ETF	2.33M	2.30%	-17.70K
Vanguard Small Cap Index	2.06M	2.04%	45.68K
BB Biotech AG Ord	2.04M	2.02%	-
T. Rowe Price Health Sciences	1.83M	1.81%	-127.14K
Fidelity Select Biotechnology	1.56M	1.54%	-105.60K
T. Rowe Price Integrated US SmCapGrEq	1.48M	1.46%	738.72K
SPDR® S&P Biotech ETF	1.46M	1.44%	-14.20K
Vanguard Small Cap Value Index Inv	1.37M	1.35%	8.08K
Vanguard Institutional Extnd Mkt Idx Tr	1.27M	1.25%	25.29K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Dec 30, 2024	CHILDS JOHN W	-	Buy	$1.04M
Oct 02, 2024	CHILDS JOHN W	-	Buy	$999.97K
Oct 02, 2024	Coric Vlad	Chief Executive Officer	Buy	$999.97K
Sep 24, 2024	Bailey Gregory	-	Buy	$220.97K
Jul 18, 2024	CHILDS JOHN W	-	Buy	$1.01M

Insider Transactions Trends

Date	Buy	Sell
2025 Q1	-	-
2024 Q4	3	-
2024 Q3	2	-
2024 Q2	10	-
2024 Q1	-	-

BHVN Ownership FAQ

Who Owns Biohaven Pharmaceutical?

Biohaven Pharmaceutical shareholders are primarily institutional investors at 90.49%, followed by 11.16% insiders and -1.65% retail investors. The average institutional ownership in Biohaven Pharmaceutical's industry, Biotech Stocks , is 109.70%, which Biohaven Pharmaceutical falls below.

Who owns the most shares of Biohaven Pharmaceutical?

Biohaven Pharmaceutical’s largest shareholders are Vanguard group (8.41M shares, 8.92%), Blackrock funding, inc. /de (7.67M shares, 8.12%), and Blackrock (6.17M shares, 7.56%). Together, they hold 24.60% of Biohaven Pharmaceutical’s total shares outstanding.

Does Blackrock own Biohaven Pharmaceutical?

Yes, BlackRock owns 7.56% of Biohaven Pharmaceutical, totaling 6.17M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 214.15M$. In the last quarter, BlackRock increased its holdings by 446.83K shares, a 7.81% change.

Who is Biohaven Pharmaceutical’s biggest shareholder by percentage of total assets invested?

Rp management is Biohaven Pharmaceutical’s biggest shareholder by percentage of total assets invested, with 64.43% of its assets in 2.94M Biohaven Pharmaceutical shares, valued at 146.74M$.

Who is the top mutual fund holder of Biohaven Pharmaceutical shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Biohaven Pharmaceutical shares, with 2.48% of its total shares outstanding invested in 2.51M Biohaven Pharmaceutical shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools